




To Master Protocol or Not To Master Protocol

Kristine Broglio, Cindy Lu, Christi Kleoudis, Kyle Wathen, Melissa Span, Elizabeth Pilling*

*Elizabeth Pilling, Biometrics, Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

June 2024



Outline


- 1** Introduction
- 2** Decision Aids and Scoring – 3 steps
- 3** Example

Aim: to identify smart opportunities for Master Protocols



Introduction

- In our drug project portfolio:
 - We may have a drug for which we're considering multiple disease indications (so basket trial could be an option)
 - Or we may have several drugs which are targeting the same disease population (so umbrella/platform could be an option)
 - These may follow different but potentially overlapping timelines



Step 1: What's Included

Capture info and see what's potentially combinable


Select which trials to continue to next step

Short Name	Asset	Asset ownership	Population	Primary Objective	Study Phase	Rand Comparator	Planned FSI date	Planned LSI date	Planned Primary Analysis
Rose	Red Drug	Me	Disease 1	Efficacy	III	Placebo	Q1 24	Q1 26	Q1 27
...	...	...	...	...	...	...	...	...	...

Short Name	Dosing method & frequency	Treatment duration	Blinded or Open Label	Planned N	Primary Endpoint	Key secondary endpoint(s)	Other complicating features,
Rose	Oral	52 weeks	Open	300	Change @ 1yr	Subgroup	NA
...	...	...	...	...	...	...	...



Step 2: Evaluate and Score



Operational Scorecard

Operational Assessment			
Sites	<i>Descriptions of each category</i>		
Accrual			
Screening			
Visit Schedules			
Endpoints and assessments			
Study Duration and Read-Outs			

- Similarity across sub-studies -> combinability -> operational efficiency
 - Can there be compromise to increase combinability?
- Some red/yellow is ok, but do recommend some gains in operational efficiency to proceed



Complexity and Study Integrity Scorecard

Complexity and Study Integrity			
Randomization			
Blinding			
Regulatory Review Issues			
Ways of Working			
Cross-Team Communication Plans			
Read-Out, Reporting, Data Sharing			
(Safety) Review Boards and Steering Committees			

Descriptions of each category

- Again no “show-stoppers”
- Question what is unique to the master protocol approach
- Question what can be managed or mitigated



Scientific and Statistical Scorecard


Scientific/Statistical Advantage	
Shared Control	
Borrowing/Pooling	
Scientific Advantages	

Descriptions of each category

- No statistical or scientific advantages are required
- However, this domain can add to the benefits of the approach



Step 3: Evaluate and Decide



Example: 3 Trials in Related Diseases

Step 1: What's Included

Asset	Ownership	Population	Phase	Randomized Comparator	Treatment Duration	Primary Endpoint	Planned N
Red Pill	My Company	Disease A	III	None	12 months	Global Scale	Unknown
Red Pill	My Company	Disease B	III	None	12 months	Global Scale	Unknown
Red Pill	My Company	Disease C	III	None	12 months	Global Scale	Unknown



Step 2: Score

Operational Scorecard	
Sites	Sites may enroll to some but not all sub-studies
Accrual	Reduce sample size depending if can pool/borrow
Screening	Same screening process across sub-studies
Visit Schedules	Same visit schedule across sub-studies
Endpoints and assessments	Some disease-specific secondaries
Study Duration and Read-Outs	FSI and read out expected to the same


Complexity and Study Integrity Scorecard	
Randomization	Not randomized
Blinding	Not required
Regulatory	Single arm phase III
Ways of Working	Internal support and resourcing
Cross-Team Communication	Same compound team across all sub-studies
Read-Out, Reporting, Data Sharing	Same readout and no issues with data sharing
Safety Review Boards, etc.	Established safety committee with oversight of whole master protocol



Step 2: Score – cont.


Scientific/Statistical Advantage Scorecard	
Shared Control	Single arm
Borrowing	May Borrow
Scientific Advantages	Unified data collection support learnings in rare disease

Step 3: Overall Evaluation



Acknowledgements

- AstraZeneca
 - Kristine Broglio
 - Elizabeth Pilling
 - Christie Kleoudis
 - Cindy Lu
- Eli Lilly
 - Melissa Spann
- Cytel
 - Kyle Wathen



- Manuscript being submitted
- Also see poster by Karin Nelander “Planning a platform phase IIb trial in MASH” to help illustrate some of these concepts



Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, www.astrazeneca.com

